SOMATROGON (Ngenla®)

Clinical Indication

Treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

Date of classification

July 2022

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.